WO2009060063A1 - Anthelmintic combination - Google Patents

Anthelmintic combination Download PDF

Info

Publication number
WO2009060063A1
WO2009060063A1 PCT/EP2008/065126 EP2008065126W WO2009060063A1 WO 2009060063 A1 WO2009060063 A1 WO 2009060063A1 EP 2008065126 W EP2008065126 W EP 2008065126W WO 2009060063 A1 WO2009060063 A1 WO 2009060063A1
Authority
WO
WIPO (PCT)
Prior art keywords
ivermectin
trichlorfon
abamectin
albendazole
sulphoxide
Prior art date
Application number
PCT/EP2008/065126
Other languages
French (fr)
Inventor
Hyun Sun Cho
Fabiando Peterson Lopes
Alvimar Costa
Original Assignee
Intervet International B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V. filed Critical Intervet International B.V.
Priority to BRPI0820260-5A priority Critical patent/BRPI0820260A2/en
Priority to CN200880114965A priority patent/CN101848710A/en
Priority to AU2008324095A priority patent/AU2008324095A1/en
Priority to MX2010004852A priority patent/MX2010004852A/en
Publication of WO2009060063A1 publication Critical patent/WO2009060063A1/en
Priority to ZA2010/02315A priority patent/ZA201002315B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Definitions

  • the present invention relates to compositions for controlling parasites, comprising a combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon and the use of such compositions in the preparation of a medicament for controlling parasites.
  • Endoparasites commonly cause clinical disease in especially in livestock animals and have significant adverse economic effects on farming economies when present at subclinical levels.
  • the most frequently encountered endoparasites are the group of worms referred to as nematodes.
  • the nematodes are found in the intestinal tract, heart, lungs, blood vessels and other body tissues of animals and are a primary cause of anemia, weight loss and malnutrition in the infected animals.
  • the nematodes most commonly found to be the infecting agents of ruminants include Haemonchus and Ostertagia generally found in abomasum; Cooperia, Trichostrongylus and Nematodirus generally found in the intestinal tract, and Dictyocaulus found in the lungs.
  • the resistance occurs when a strain of a parasite is able to tolerate doses of an active ingredient that is efficacious against other populations of parasites of the same species. This characteristic is inheritable.
  • Avermectins are well known anthelmintic compounds, belonging to the class of macrocyclic lactones.
  • the avermectins are isolated from fermentation products of Streptomyces avemitilis and ivermectin is a compound which is a semisynthetic chemical compound formed by modification of avermectin.
  • the basic structure of the avermectins is a 16-membered lactone ring to which are appended three main substituent groups: a hexahydrobenzofuran group, a disaccharide group (at C-13) and a spiroketal ring (C-17 to C-28).
  • the avermectin series of compounds including ivermectin, abamectin, doramectin, eprinomectin and selamectin, are potent anthelmintic and antiparasitic agents against internal and external parasites (endectocides).
  • avermectins are disclosed in US-A-4,310, 519 to Albers Schonberg et al., and the 22,23-dihydro avermectin compounds are disclosed in Chabala et al, US-A- 4,199, 569.
  • Albendazole sulphoxide (also known as ricobendazole) is a benzimidazole carbamate which is used as a broad spectrum anthelmintic in veterinary medicine.
  • the preparation and certain uses of albendazole sulphoxide are disclosed in U.S. Pat. No. US 3,915,86. It is also the metabolite of two other veterinary drugs: netobimin and albendazole.
  • Albendazole is the generic name for [5-(propylthio)-1 H- benzimidazol-2-yl)]carbamic acid methyl ester.
  • the preparation and certain uses of albendazole are disclosed in U.S. Pat. No. 3,915,986.
  • Trichlorfon (O,O-dimethyl-(2,2,2-trichloro-1-hydroxyethyl)-phosphonale dimethyl 2,2,2,2-trichloro-1-hydroxyethyl-phosphonate, also called metrifonate is an organophosphorous compound having potent anticholinesterase activity and is administered topically as an ectoparasiticide or orally as an anthelmintic.
  • Organophosphates as antiparasitic agents are e.g. dichlorvos, coumaphos, crufomate or haloxon.
  • Organophosphates act as cholinesterase inhibitor by irreversible inactivation of acetylcholinesterase, leading to excessive cholinergic activity at relevant sites.
  • the present invention concerns an anthelmintic composition, which comprises a combination of ivermectin, abamectin, albenazole sulphoxide and trichlorfon.
  • the present invention provides an antiparasitic composition, which comprises as active ingredient, an effective amount of a combination of ivermectin, abamectin, albendazole suphoxide and trichlorfon in the following concentrations: 0.02-1.0% or 0.05- 0.25% w/w ivermectin, 0.01-0.5%, or 0.05-0.25% w/w abamectin, 0.3 - 15%, or 1.0% - 2.5% w/w albendazole sulphoxide and 10-70 %, or 15- 60% w/w trichlorfon.
  • the invention includes pharmaceutically acceptable salts of the compounds.
  • Pharmacologically intolerable salts which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, are converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.
  • the active ingredients may be present in the dosage form as true mixtures, but they may also be administered individually in separate dosage forms and form mixtures only when they are in the host animal.
  • the pharmaceutical composition can be in a form suitable for oral or intraruminal administration, as a solid dosage form, a liquid suspension, or a paste.
  • Conventional liquid formulations for oral administration are usually solutions, suspensions or emulsions of the active ingredients together with suitable diluents, solvents, flavours and colours to form a dosage form.
  • the composition is in the form of a powder for extemporaneous suspension. This powder is suspended in water or in a suspension containing active ingredients before oral administration to the animal.
  • the particular amount of the anthelminthic compound required for a particular treatment will vary, depending upon the species, age and weight of the animal being treated, the particular parasite to be guarded against, or treated, as well as the specific organophosphate compound selected for the treatment, the route and the frequency of administration. Anthelminthics are frequently delivered to ruminants in the form of oral drenches directly into the rumen.
  • w/v weight/weight, i.e. “1 % w/v” means 1 g in 100 g of the composition, "v/v” means volume per volume, and 1% v/v means 1 ml, in a total of 100 ml.
  • composition comprising 0.1% ivermectin, 0.05% abamectin, 20% trichlorfon and 1.5% albendazole sulphoxide.
  • a recommended dosage is 2 ml of the aqueous suspension based on the powder formulation described above per 5 kg body weight of the animal.
  • novel compositions according to the invention have proven good efficacy against internal parasites, especially in sheep and goats.
  • the novel compositions according to the invention result in a unique formulation which controls parasites resistant to ivermectin and doramectin, like, Cooperia spp. and Haemonchus spp.
  • compositions of the invention may be used for the preparation of a medicament for controlling parasites in and on host animals, particularly in ruminants such as sheep, cattle and goats.
  • methylparaben methylparaben, propylparaben, sodium laurylsulfate or other wettable surfactant, aluminum hydroxide dry, Aerosil 200, albendazole sulphoxide, ivermectin and abamectin. Stir until getting homogeneous suspension. Trichlorfon is added at the moment of using.
  • the following solid ingredients are introduced sequentially into a vessel containing water and with the stirring: methylparaben, propylparaben. Aerosil 200, albendazole sulphoxide, ivermectin and abamectin. Stir until getting homogeneous suspension and add the mixture of water, polysorbate, antifoam and ethanol. Trichlorfon is added at the moment of using.
  • the combination according to the invention showed a egg per gram (e p g) reduction in sheep on Day 3 of 97.0 % compared with 84% for trichlorfon, 66.1 % for albendazole sulphoxide, 63.8% for ivermectin and 30% for abamectin alone.
  • Efficacy on e.p.g. reduction in sheep was evaluated for the combination of 0.1 % ivermectin, 0.1% abamectin, 3% albendazole sulphoxide and either 20% or 25% trichlorfon compared with the commercial product TRIMIX of Merial containing 200 mcg/kg ivermectin, 7,5 mg/kg levamisole, 5 mg/kg albendazole .
  • Trichlorfon showed a e.p.g. reduction in sheep on Day 3 of 99.5% % and 100% for Trichlorfon 25 % compared with 92.2% for TRIMIX.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for controlling parasites, comprising a combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon and the use of such compositions in the preparation of a medicament for controlling endoparasites.

Description

Anthelmintic combination
The present invention relates to compositions for controlling parasites, comprising a combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon and the use of such compositions in the preparation of a medicament for controlling parasites.
Endoparasites commonly cause clinical disease in especially in livestock animals and have significant adverse economic effects on farming economies when present at subclinical levels. The most frequently encountered endoparasites are the group of worms referred to as nematodes. The nematodes are found in the intestinal tract, heart, lungs, blood vessels and other body tissues of animals and are a primary cause of anemia, weight loss and malnutrition in the infected animals. The nematodes most commonly found to be the infecting agents of ruminants include Haemonchus and Ostertagia generally found in abomasum; Cooperia, Trichostrongylus and Nematodirus generally found in the intestinal tract, and Dictyocaulus found in the lungs.
Treatment of animals to prevent infestation by any of the above-mentioned parasites, or to reduce or control the proliferation of these parasites in animals is thus important.
Meanwhile the problem has arisen that some parasites develop a resistance to antiparasitic drugs like ivermectin. The resistance occurs when a strain of a parasite is able to tolerate doses of an active ingredient that is efficacious against other populations of parasites of the same species. This characteristic is inheritable.
After the use of macrocyclic lactones for almost two decades in cattle in Brazil several reports on resistant endoparasites in sheep, cattle and goats were published. The discovery of novel anti-parasitics with equal or better qualities than macrocyclic lactones seems to be a distant reality in the veterinary pharmaceutical industry.
Therefore, the chemical groups available nowadays must be used in a rational way, with a view to achieving high percentages of efficacy against endoparasites, especially in ruminants and delaying the occurrence of resistant strains. Avermectins are well known anthelmintic compounds, belonging to the class of macrocyclic lactones. The avermectins are isolated from fermentation products of Streptomyces avemitilis and ivermectin is a compound which is a semisynthetic chemical compound formed by modification of avermectin. The basic structure of the avermectins is a 16-membered lactone ring to which are appended three main substituent groups: a hexahydrobenzofuran group, a disaccharide group (at C-13) and a spiroketal ring (C-17 to C-28). The avermectin series of compounds, including ivermectin, abamectin, doramectin, eprinomectin and selamectin, are potent anthelmintic and antiparasitic agents against internal and external parasites (endectocides). The natural product avermectins are disclosed in US-A-4,310, 519 to Albers Schonberg et al., and the 22,23-dihydro avermectin compounds are disclosed in Chabala et al, US-A- 4,199, 569.
Albendazole sulphoxide (also known as ricobendazole) is a benzimidazole carbamate which is used as a broad spectrum anthelmintic in veterinary medicine. The preparation and certain uses of albendazole sulphoxide are disclosed in U.S. Pat. No. US 3,915,86. It is also the metabolite of two other veterinary drugs: netobimin and albendazole. Albendazole is the generic name for [5-(propylthio)-1 H- benzimidazol-2-yl)]carbamic acid methyl ester. The preparation and certain uses of albendazole are disclosed in U.S. Pat. No. 3,915,986.
Trichlorfon (O,O-dimethyl-(2,2,2-trichloro-1-hydroxyethyl)-phosphonale dimethyl 2,2,2,2-trichloro-1-hydroxyethyl-phosphonate, also called metrifonate is an organophosphorous compound having potent anticholinesterase activity and is administered topically as an ectoparasiticide or orally as an anthelmintic.
Examples of other organophosphates as antiparasitic agents are e.g. dichlorvos, coumaphos, crufomate or haloxon. Organophosphates act as cholinesterase inhibitor by irreversible inactivation of acetylcholinesterase, leading to excessive cholinergic activity at relevant sites.
It has now been found that the combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon result in such a broad-spectrum anthelmintic composition with activity against resistant nematode species.
The present invention concerns an anthelmintic composition, which comprises a combination of ivermectin, abamectin, albenazole sulphoxide and trichlorfon.
In one embodiment the present invention provides an antiparasitic composition, which comprises as active ingredient, an effective amount of a combination of ivermectin, abamectin, albendazole suphoxide and trichlorfon in the following concentrations: 0.02-1.0% or 0.05- 0.25% w/w ivermectin, 0.01-0.5%, or 0.05-0.25% w/w abamectin, 0.3 - 15%, or 1.0% - 2.5% w/w albendazole sulphoxide and 10-70 %, or 15- 60% w/w trichlorfon.
The invention includes pharmaceutically acceptable salts of the compounds.
Pharmacologically intolerable salts which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, are converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.
In order to form the composition according to the invention the active ingredients may be present in the dosage form as true mixtures, but they may also be administered individually in separate dosage forms and form mixtures only when they are in the host animal.
The pharmaceutical composition can be in a form suitable for oral or intraruminal administration, as a solid dosage form, a liquid suspension, or a paste. Conventional liquid formulations for oral administration are usually solutions, suspensions or emulsions of the active ingredients together with suitable diluents, solvents, flavours and colours to form a dosage form.
In one embodiment the composition is in the form of a powder for extemporaneous suspension. This powder is suspended in water or in a suspension containing active ingredients before oral administration to the animal.
The particular amount of the anthelminthic compound required for a particular treatment will vary, depending upon the species, age and weight of the animal being treated, the particular parasite to be guarded against, or treated, as well as the specific organophosphate compound selected for the treatment, the route and the frequency of administration. Anthelminthics are frequently delivered to ruminants in the form of oral drenches directly into the rumen.
By "w/v" is meant weight/weight, i.e. "1 % w/v" means 1 g in 100 g of the composition, "v/v" means volume per volume, and 1% v/v means 1 ml, in a total of 100 ml.
Good results were obtained with a composition comprising 0.1% ivermectin, 0.05% abamectin, 20% trichlorfon and 1.5% albendazole sulphoxide. A recommended dosage is 2 ml of the aqueous suspension based on the powder formulation described above per 5 kg body weight of the animal.
The novel compositions according to the invention have proven good efficacy against internal parasites, especially in sheep and goats. The novel compositions according to the invention result in a unique formulation which controls parasites resistant to ivermectin and doramectin, like, Cooperia spp. and Haemonchus spp.
The compositions of the invention may be used for the preparation of a medicament for controlling parasites in and on host animals, particularly in ruminants such as sheep, cattle and goats.
EXAMPLES: Suspension formulation
Example 1 :
A B
Trichlorfon 50.Og 5Og
Albendazole sulphoxide 3.Og 3.Og
Ivermectin 0.1g 0.2g
Abamectin 0.1g 0.1 g
Method to manufacture formulation 1 :
The following ingredients are introduced sequentially into a vessel containing water and with the stirring: methylparaben, propylparaben, sodium laurylsulfate or other wettable surfactant, aluminum hydroxide dry, Aerosil 200, albendazole sulphoxide, ivermectin and abamectin. Stir until getting homogeneous suspension. Trichlorfon is added at the moment of using.
Example 2
A B
Trichlorfon 25g 25%
Albendazole sulphoxide 1.5g 1.5%
Ivermectin 0.1g 0.2%
Abamectin 0.1g 0.1 %
Method to manufacture formulation 2:
The following ingredients are introduced sequentially into a vessel containing water and with stirring: polysorbate, propyleneglycol, Albendazole sulphoxide, ivermectin and abamectin. Add methylparaben and propylparaben in ethanol and antifoam. Stir until get homogeneous suspension and add hydroxyethylcellulose hydrated. Trichlorfon is added at the moment of using. Example 3:
A B
Trichlorfon 5Og 25g
Albendazole sulphoxide 3.Og 1.5g
Ivermectin 0.2g 0.1g
Abamectin 0.1 g 0.05g
Method to manufacture formulation 3:
The following solid ingredients are introduced sequentially into a vessel containing water and with the stirring: methylparaben, propylparaben. Aerosil 200, albendazole sulphoxide, ivermectin and abamectin. Stir until getting homogeneous suspension and add the mixture of water, polysorbate, antifoam and ethanol. Trichlorfon is added at the moment of using.
Example 4
AA B
Trichorfon 20.0% 50%
Albendazole sulphoxide 1.5% 3.0%
Ivermectin 0.1 % 0.2%
Abamectin 0.05% 0.1 % Method to manufacture formulation 4
The following ingredients are introduced sequentially into a vessel containing water and with the stirring: sodium citrate, Carboxymethylcellulose, Polyvinylpyrrolidone and Aerosil 200. Stir until getting homogenous dispersion and add a solution of methylparaben and propylparaben dissolved in benzyl alcohol. Stir and add albendazole sulfoxide, abamectin and ivermectin. Trichlorfon is added at the moment of using. Experiment 1
An field trial experiment conducted in naturally infected sheep demonstrated that the combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon according to the invention showed a higher anthelminthic efficacy compared to TRIMIX, Merial containing 200 mcg/kg ivermectin, 7,5 mg/kg levamisole, 5 mg/kg albendazole and CYDECTIN injectable, Fort Dodge Animal Health, containing Moxidectin, both commercial formulations, against the following species of endoparasites: Haemonchus contortus (both Trimex and Cydectin) and S.papillosus (Cydectin), All formulations showed a 100% efficacy against the other species on the 14th day post treatment for C. pectinata, C. curticei, C. spatulata, T. axei, O. columbianum and Trichuris ovis.
Experiment 2 An field trial experiment conducted in naturally infected sheep demonstrated that the combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon according to the invention showed a higher anthelminthic efficacy, when compared to TRIMIX of Merial, containing 200 mcg/kg ivermectin, 7,5 mg/kg levamisole, 5 mg/kg albendazole and CYDECTIN oral, Fort Dodge Animal Health containing Moxidectin, both commercial formulations, against the following species of endoparasites: Haemonchus contortus (Cydectin) , T. axei (Cydectin) and S.papillosus (Cydectin),
All formulations showed a 100% efficacy against the other species on the 14th day post treatment for C. curticei, C. bovis, O. columbianum and Trichuris ovis.
Experiment 3
An field trial experiment conducted in naturally infected goat demonstrated that the combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon showed a higher anthelminthic efficacy, when compared to TRIMIX of Merial and CYDECTIN injectable, Fort Dodge Animal Health, containing Moxidectin, both commercial formulations, against the following species of endoparasites: T. ovis (Cydectin), C. bovis (Cydectin).
All formulations showed a 100% efficacy against the other species on the 14th day post treatment for H. contortus, T. axei, T. columbriformis, O. columbianum.
Experiment 4
An field trial experiment conducted in naturally infected goat demonstrated that the combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon showed a higher anthelminthic efficacy, when compared to TRIMIX of Merial containing 200 mcg/kg ivermectin, 7,5 mg/kg levamisole, 5 mg/kg albendazole and CYDECTIN oral, Fort Dodge Animal Health, containing Moxidectin, both commercial formulations, against the following species of endoparasites: Haemonchus contortus (both Trimex and Cydectin), T. ovis (Cydectin) and S.papillosus (Cydectin),
All formulations showed a 100% efficacy against the other species on the 14th day post treatment for C. curticei, C. spatulata, T. axei, T. colubriformis and O. columbianum.
Experiment 5
Efficacy on e.p.g. reduction in sheep The efficacy of a combination of 0.1 % ivermectin, 0.1 % abamectin, 3% albendazole sulphoxide and 50% trichlorfon was compared with ivermectin, abamectin, albendazole sulphoxide and trichlorfon alone in 4 animals per group
The combination according to the invention showed a egg per gram (e p g) reduction in sheep on Day 3 of 97.0 % compared with 84% for trichlorfon, 66.1 % for albendazole sulphoxide, 63.8% for ivermectin and 30% for abamectin alone. Experiment 6
Efficacy on e.p.g. reduction in sheep
Efficacy on e.p.g. reduction in sheep was evaluated for the combination of 0.1 % ivermectin, 0.1% abamectin, 3% albendazole sulphoxide and either 20% or 25% trichlorfon compared with the commercial product TRIMIX of Merial containing 200 mcg/kg ivermectin, 7,5 mg/kg levamisole, 5 mg/kg albendazole .
The combination with 20% Trichlorfon showed a e.p.g. reduction in sheep on Day 3 of 99.5% % and 100% for Trichlorfon 25 % compared with 92.2% for TRIMIX.

Claims

CLAIMS:
1. Anthelminthic composition, which comprises a combination of ivermectin, abamectin, albendazole sulphoxide and trichlorfon.
2. The composition according to claim 1 , characterized in that it comprises 0.1%w/w ivermectin , 0.05 %w/w abamectin, 1.5% w/w albendazole sulphoxide and 20% w/w trichlorfon.
3. The composition according to any of claims 1 or 2, characterised in that the composition is in is the form of a powder for extemporaneous suspension.
4. Use of a composition according to any of claims 1 to 3 for the preparation of a medicament for controlling endoparasites in host animals.
5. Use according to claim 4 characterized in that the composition is administered to the host animal orally.
6. Use according to claim 4 or 5 characterized in that the host animal is a ruminant.
7. Use according to claim 4 to 6 characterized in that the host animal is a sheep or a goat.
PCT/EP2008/065126 2007-11-09 2008-11-07 Anthelmintic combination WO2009060063A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0820260-5A BRPI0820260A2 (en) 2007-11-09 2008-11-07 Anthelmintic composition and use of composition
CN200880114965A CN101848710A (en) 2007-11-09 2008-11-07 Anthelmintic combination
AU2008324095A AU2008324095A1 (en) 2007-11-09 2008-11-07 Anthelmintic combination
MX2010004852A MX2010004852A (en) 2007-11-09 2008-11-07 Anthelmintic combination.
ZA2010/02315A ZA201002315B (en) 2007-11-09 2010-03-31 Anthelmintic combination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07120380 2007-11-09
EP07120380.6 2007-11-09

Publications (1)

Publication Number Publication Date
WO2009060063A1 true WO2009060063A1 (en) 2009-05-14

Family

ID=39059330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/065126 WO2009060063A1 (en) 2007-11-09 2008-11-07 Anthelmintic combination

Country Status (7)

Country Link
CN (1) CN101848710A (en)
AR (1) AR069223A1 (en)
AU (1) AU2008324095A1 (en)
BR (1) BRPI0820260A2 (en)
MX (1) MX2010004852A (en)
WO (1) WO2009060063A1 (en)
ZA (1) ZA201002315B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027333A1 (en) * 2009-09-07 2011-03-10 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
WO2013095286A3 (en) * 2011-12-20 2013-11-07 Christer Edlund Synergistic combination comprising avermectins and a nsaid for tumor inhibition
RU2699799C1 (en) * 2019-01-10 2019-09-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Antiparasitic composition and a method for use thereof for treating parasitosis of ruminant animals
CN114569561A (en) * 2022-03-28 2022-06-03 中牧实业股份有限公司黄冈动物药品厂 Albendazole ivermectin powder and preparation method and application thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102743403A (en) * 2012-06-26 2012-10-24 格特生物制药（天津）有限公司 Parasite expelling tablet for domestic animals and preparation method thereof
CN102726443B (en) * 2012-07-12 2013-11-27 中国林业科学研究院亚热带林业研究所 Ivermectin and dipterex compound pesticide
CN113755610B (en) * 2021-10-08 2023-09-12 内蒙古自治区农牧业科学院 Gene for detecting sensitivity of haemonchus contortus to ivermectin and application
CN114452314A (en) * 2022-01-12 2022-05-10 河南百草元兽药有限公司 Albendazole ivermectin powder and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194832A (en) * 1997-03-27 1998-10-07 王玉万 Antiparasitic medicine containing avermectin/ivermectin for animals
WO2004069242A1 (en) * 2003-02-05 2004-08-19 Jurox Pty Ltd Anthelmintic composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194832A (en) * 1997-03-27 1998-10-07 王玉万 Antiparasitic medicine containing avermectin/ivermectin for animals
WO2004069242A1 (en) * 2003-02-05 2004-08-19 Jurox Pty Ltd Anthelmintic composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2000, "Antiparasitic compositzions containing avermectin / ivermectin for veterinary use", XP002469864, retrieved from STN Database accession no. 2000:246638 *
WRIGLEY J ET AL: "Resistance to a triple combination of broad-spectrum anthelmintics in naturally-acquired Ostertagia circumcincta infections in sheep.", NEW ZEALAND VETERINARY JOURNAL FEB 2006, vol. 54, no. 1, February 2006 (2006-02-01), pages 47 - 49, XP009110069, ISSN: 0048-0169 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027333A1 (en) * 2009-09-07 2011-03-10 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
AU2020202781B2 (en) * 2009-09-07 2021-05-13 Argenta Innovation Limited Granulated anthelmintic preparations and delivery systems
US11253593B2 (en) 2009-09-07 2022-02-22 Argenta Innovation Limited Granulated anthelmintic preparations and delivery systems
AU2022200149B2 (en) * 2009-09-07 2023-06-15 Argenta Innovation Limited Granulated anthelmintic preparations and delivery systems
WO2013095286A3 (en) * 2011-12-20 2013-11-07 Christer Edlund Synergistic combination comprising avermectins and a nsaid for tumor inhibition
AU2012354236B2 (en) * 2011-12-20 2017-10-05 Ectin Research Ab Synergistic combination comprising avermectins and a NSAID for tumor inhibition
US9782424B2 (en) 2011-12-20 2017-10-10 Ectin Research Ab Synergistic combination comprising avermectins and a NSAID for tumor inhibition
RU2699799C1 (en) * 2019-01-10 2019-09-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Antiparasitic composition and a method for use thereof for treating parasitosis of ruminant animals
CN114569561A (en) * 2022-03-28 2022-06-03 中牧实业股份有限公司黄冈动物药品厂 Albendazole ivermectin powder and preparation method and application thereof

Also Published As

Publication number Publication date
MX2010004852A (en) 2010-06-02
ZA201002315B (en) 2010-11-24
AU2008324095A1 (en) 2009-05-14
AR069223A1 (en) 2010-01-06
BRPI0820260A2 (en) 2015-05-26
CN101848710A (en) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2009060063A1 (en) Anthelmintic combination
EP2170321B1 (en) Anthelmintic combination
JPS6121453B2 (en)
EP3277303B1 (en) Anthelmintic combinations and methods of use thereof
US20060121072A1 (en) Topical parasiticide formulations and methods of treatment
DK1957040T3 (en) Non-aqueous benzimidazolsammensætninger
JP3862938B2 (en) Anthelmintic composition
EP0290998B1 (en) Anticoccidial composition
AU2011268899C1 (en) Injectable formulation of a macrocyclic lactone and levamisole
AU2022268378A1 (en) Injectable formulation of a macrocyclic lactone and levamisole
AU2004281551B2 (en) Compositions for controlling parasites comprising a combination of abamectin and ivermectin
WO2015053636A1 (en) Veterinary formulations and methods
AU2003275779B2 (en) Topical parasiticide formulations and methods of treatment
WO2010126857A1 (en) Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
MXPA00006760A (en) Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114965.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847300

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 584293

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008324095

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008324095

Country of ref document: AU

Date of ref document: 20081107

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004852

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2592/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08847300

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: PI0820260

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100506